Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening
Language English Country Netherlands Media print-electronic
Document type Case Reports, Journal Article
PubMed
31288153
DOI
10.1016/j.intimp.2019.105728
PII: S1567-5769(19)30870-7
Knihovny.cz E-resources
- Keywords
- Acute kidney injury, Chemotherapy rechallenge, Immune haemolytic anemia, Oxaliplatin, Type II hypersensitivity reaction,
- MeSH
- Adenocarcinoma complications diagnosis drug therapy MeSH
- Acute Kidney Injury MeSH
- Antineoplastic Agents adverse effects therapeutic use MeSH
- Desensitization, Immunologic MeSH
- Hemolysis MeSH
- Adrenal Cortex Hormones therapeutic use MeSH
- Drug Hypersensitivity diagnosis drug therapy etiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Rectal Neoplasms complications diagnosis drug therapy MeSH
- Drug-Related Side Effects and Adverse Reactions diagnosis drug therapy etiology MeSH
- Oxaliplatin adverse effects therapeutic use MeSH
- Aged MeSH
- Thrombocytopenia MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Antineoplastic Agents MeSH
- Adrenal Cortex Hormones MeSH
- Oxaliplatin MeSH
BACKGROUND: Rechallenge with oxaliplatin is common in the treatment of colorectal cancer and increases the risk of a detrimental oxaliplatin-induced immune reaction. Allergic reactions to oxaliplatin may be partially avoided by desensitization protocols involving immune suppressive drugs, slow administration and gradually increasing chemotherapeutic doses. However, non-IgE-mediated immunopathologic reactions to oxaliplatin remain challenging and may be potentially life-threatening. CASE PRESENTATION: Here we report two potentially fatal cases of type II hypersensitivity to oxaliplatin in metastatic colorectal cancer patients. Both patients manifested with severe thrombocytopenia, intravascular haemolysis, and acute kidney injury 4-6 h after oxaliplatin administration in a rechallenge setting. Serology revealed that the reactive entity for immune haemolysis was an IgG oxaliplatin-induced antibody. The course of anti-cancer treatment and severe adverse event after oxaliplatin rechallenge including diagnostic dilemma and the results of detailed routine clinical chemistry and hematology testing are described. Extended immunohaematology/serology testing revealed that the oxaliplatin-induced IgG antibody was present in the circulation prior to the onset of hypersensitivity, persisted for months and elicited cross-reactivity with other platinum agents. CONCLUSION: Development of type II hypersensitivity reaction manifesting as a sudden onset of severe thrombocytopenia and immune haemolysis must be considered in patients treated with oxaliplatin, especially those on long-term therapy or when rechallenged. Step-wise diagnosis involves clinical presentation, detection of haemolysis in patient's blood and/or urine, evaluation of platelet count, and direct anti-globulin Coombs test.
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Laboratory Medicine Masaryk Memorial Cancer Institute Brno Czech Republic
References provided by Crossref.org
